Sami Ullah Mumtaz, Somia Iqtadar, Zafar Niaz, Tayyeba Komal, Sajid Abaidullah.
Mean Blood Ammonia Level After Treatment with Rifaximin Versus Neomycin in Chronic Liver Disease patients Presenting with Hepatic Encephalopathy.
Ann King Edward Med Uni Jan ;25(1):37-40.

Abstract | Objective: To compare Rifaximin versus neomycin in chronic liver disease (CLD) patients presenting with hepatic Encephalopathy. Methodology: This Randomized controlled trial was conducted at North Medical Ward, King Edward Medical University/ Mayo Hospital Lahore from June to December 2013. Total 100 patients of CLD with Hepatic Encephalopathy were included through non-probability, purposive sampling and were named group A & B by random division. In Group A, patients received conventional Antibiotic Neomycin 3000mg 6- hourly daily while in Group B; patients received Rifaximin 600mg 12-hourly daily orally for 21 days. Blood Ammonia levels of both groups after 21 days treatment were analyzed by the software SPSS version 16. Results: The mean age of patients was 54.23±13.70 years with54 (54%) male and 46 (46%) females. Out of 54 male patients, 28 (52%) were randomized to Rifaximin and 26 (48%) were randomized to Neomycin. Similarly, out of 46 female patients, 22 (48%) were randomized to Rifaximin and 24 (52%) were randomized to Neomycin. The serum Ammonia level after treatment with Rifaximin was 58.00 (14-117) g/dl whereas with Neomycin was 87.00(38-381) g/dl. Significant difference was found between both groups (pvalue< 0.0001). Conclusion: Rifaximin is a better treatment option in CLD patients with Hepatic Encephalopathy as compared to conventional Neomycin.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com